PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer
Top Cited Papers
Open Access
- 15 June 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (12), 3577-3584
- https://doi.org/10.1158/1078-0432.ccr-06-1609
Abstract
Purpose: The phosphatidylinositol 3′-kinase/Akt pathway is frequently altered in breast cancer. PTEN, a phosphatase that opposes the effect of phosphatidylinositol 3′-kinase, can be mutated or lost, whereas the PIK3CA gene is mutated. These have been proposed as alternative mechanisms, and their clinicalpathology significance is under discussion. In this study, we aimed to explore whether PIK3CA mutations and PTEN loss are mutually exclusive mechanisms, correlate with other known clinicopathologic markers, or have clinical implication in breast cancer.Keywords
This publication has 47 references indexed in Scilit:
- The association between Akt activation and resistance to hormone therapy in metastatic breast cancerEuropean Journal Of Cancer, 2006
- Mutation of the PIK3CA oncogene in human cancersBritish Journal of Cancer, 2006
- PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinomaThe Journal of Pathology, 2005
- PIK3CA mutations in breast cancer are associated with poor outcomeBreast Cancer Research and Treatment, 2005
- The prevalence of PIK3CA mutations in gastric and colon cancerEuropean Journal Of Cancer, 2005
- Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistanceBreast Cancer Research and Treatment, 2005
- Frequent Mutation of the PIK3CA Gene in Ovarian and Breast CancersClinical Cancer Research, 2005
- PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast CarcinomaCancer Research, 2005
- Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissuesEuropean Journal Of Cancer, 2001
- c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancerEuropean Journal Of Cancer, 1995